TPP1 and infection: An article outlining practical aspects of intracerebroventricular enzyme replacement therapy for CLN2 disease, based on 6 years of experience in treating 48 patients at the University Medical Center Hamburg-Eppendorf, showed that infection rates (also observed in our analysis as a secondary cause of an adverse reaction) and technical complications can be minimized and termination of treatment be avoided with strict adherence to best practice guidelines [28].